NZ746796A - Peritoneal dialysate purity control system - Google Patents
Peritoneal dialysate purity control systemInfo
- Publication number
- NZ746796A NZ746796A NZ746796A NZ74679618A NZ746796A NZ 746796 A NZ746796 A NZ 746796A NZ 746796 A NZ746796 A NZ 746796A NZ 74679618 A NZ74679618 A NZ 74679618A NZ 746796 A NZ746796 A NZ 746796A
- Authority
- NZ
- New Zealand
- Prior art keywords
- peritoneal dialysate
- peritoneal
- fluid
- mmhg
- control system
- Prior art date
Links
- 239000012530 fluid Substances 0.000 claims abstract description 215
- 239000012141 concentrate Substances 0.000 claims abstract description 180
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 155
- 239000002357 osmotic agent Substances 0.000 claims abstract description 72
- 238000000502 dialysis Methods 0.000 claims abstract description 55
- 150000002500 ions Chemical class 0.000 claims abstract description 38
- 238000000746 purification Methods 0.000 claims abstract description 33
- 239000002699 waste material Substances 0.000 claims description 65
- 239000002594 sorbent Substances 0.000 claims description 49
- 230000001276 controlling effect Effects 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 81
- 230000001954 sterilising Effects 0.000 description 54
- 239000000243 solution Substances 0.000 description 50
- 230000000249 desinfective Effects 0.000 description 45
- 229960001031 Glucose Drugs 0.000 description 44
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 44
- 238000001802 infusion Methods 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- 229920002177 Icodextrin Polymers 0.000 description 27
- 229940016836 icodextrin Drugs 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 210000003200 Peritoneal Cavity Anatomy 0.000 description 24
- 238000007792 addition Methods 0.000 description 24
- 239000008121 dextrose Substances 0.000 description 24
- 238000003860 storage Methods 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000007789 gas Substances 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 13
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 12
- NGSFWBMYFKHRBD-UHFFFAOYSA-M Sodium lactate Chemical compound [Na+].CC(O)C([O-])=O NGSFWBMYFKHRBD-UHFFFAOYSA-M 0.000 description 11
- 230000036512 infertility Effects 0.000 description 11
- 231100000803 sterility Toxicity 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 10
- 239000000356 contaminant Substances 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 229940005581 Sodium Lactate Drugs 0.000 description 9
- 239000001540 sodium lactate Substances 0.000 description 9
- 235000011088 sodium lactate Nutrition 0.000 description 9
- 210000004379 Membranes Anatomy 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- KFSLWBXXFJQRDL-UHFFFAOYSA-N peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- 230000000813 microbial Effects 0.000 description 7
- 238000005086 pumping Methods 0.000 description 7
- 206010034674 Peritonitis Diseases 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 238000001631 haemodialysis Methods 0.000 description 6
- 230000000322 hemodialysis Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 5
- 239000000385 dialysis solution Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N al2o3 Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial Effects 0.000 description 4
- 239000007844 bleaching agent Substances 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 229960002337 magnesium chloride Drugs 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 235000011147 magnesium chloride Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000001223 reverse osmosis Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 229940001447 Lactate Drugs 0.000 description 3
- 229960002713 calcium chloride Drugs 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 229960002897 Heparin Drugs 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229940091250 Magnesium supplements Drugs 0.000 description 2
- 210000004303 Peritoneum Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000012206 bottled water Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- -1 hydroxyl ions Chemical class 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 150000008040 ionic compounds Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- LGNWNHXUNNLICK-HXIISURNSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O LGNWNHXUNNLICK-HXIISURNSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229940024606 Amino Acids Drugs 0.000 description 1
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 229940050906 Magnesium chloride hexahydrate Drugs 0.000 description 1
- 206010067594 Peritoneal dialysis complication Diseases 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000020112 bottled filtered water Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium;dichloride;dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- DTYCRHCCLVCUDT-UHFFFAOYSA-J calcium;magnesium;tetrachloride Chemical compound [Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[Ca+2] DTYCRHCCLVCUDT-UHFFFAOYSA-J 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000008214 highly purified water Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000000396 hypokalemic Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012569 microbial contaminant Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 235000014366 other mixer Nutrition 0.000 description 1
- 210000000505 parietal peritoneum Anatomy 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229960001407 sodium bicarbonate Drugs 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 210000000504 visceral peritoneum Anatomy 0.000 description 1
Abstract
A purity control system for use in peritoneal dialysis, the purity and control system comprising: a first fluid line fluidly connected to a peritoneal dialysate generation system and a first ultrafilter; a second fluid line fluidly connecting the first ultrafilter to a second ultrafilter; the peritoneal dialysate generation system comprising at least a water source, an osmotic agent source, an ion concentrate source, and a water purification module fluidly connected to a peritoneal dialysate generation flow path. neal dialysate generation system comprising at least a water source, an osmotic agent source, an ion concentrate source, and a water purification module fluidly connected to a peritoneal dialysate generation flow path.
Description
PERITONEAL DIALYSATE PURITY CONTROL SYSTEM
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of and priority to U.S. Patent Application
No. 15/723,764, filed October 3, 2017. U.S. Patent Application No. 15/723,764 is a
continuation in part of U.S. Patent Application No. 15/478,569 filed April 4, 2017, which claims
benefit of and priority to U.S. Provisional Application No. 62/318,173 filed April 4, 2016, and
the disclosures of each of the above-identified applications are hereby incorporated by reference
in their entirety.
FIELD OF THE INVENTION
The invention relates to devices, systems, and methods for generating a peritoneal
dialysate having purity and sterility characteristics suitable for Peritoneal Dialysis (PD). The
peritoneal dialysate can be generated from water of variable quality using a purity control
system having one or more ultrafilters for sterilization of the peritoneal dialysate Peritoneal
dialysate generation system and related methods are described that can generate sterilized
peritoneal dialysate and deliver peritoneal dialysis therapy to a patient.
BACKGROUND
Peritoneal Dialysis (PD), including Automated Peritoneal Dialysis (APD) and
Continuous Ambulatory Peritoneal Dialysis (CAPD), can be performed in a clinic or in an at
home setting, either by a patient alone or with a care-giver. PD differs from Hemodialysis (HD)
in that blood is not removed from the body and passed through a dialyzer, but rather a catheter is
placed in the peritoneal cavity and dialysate introduced directly into the peritoneal cavity.
Blood is cleaned inside the patient using the patient’s own peritoneum as a type of dialysis
membrane. However, because fluid is directly introduced into a human body, the fluid used for
peritoneal dialysate is generally required to be free of biological and chemical contaminants.
The peritoneal dialysate should also contain specified concentrations of solutes and cations for
biocompatibility and for performing membrane exchange.
Peritonitis is a serious and common problem in the PD population that results in
abdominal pain, fever, and cloudy dialysate. Peritonitis remains a leading complication of PD
21349709_1:hxa
with around 18% of infection-related mortality in PD patients resulting from peritonitis (Fried et
al., “Peritonitis influences mortality in peritoneal dialysis patients,” J. Am. Soc. Nephrol. 1996;
7:2176–2182). Moreover, peritonitis is a contributing factor to death in 16% of deaths on PD,
and remains a major cause for patients discontinuing PD and switching to HD. Peritonitis and
other peritoneal dialysis complications can often be traced to non-sterile techniques and/or
contaminated starting dialysate.
The US FDA regulates pre-packaged dialysate for use in PD as a Class II drug if the pre-
packaged dialysate is used in either a semi-automatic PD system or an automatic PD system
(e.g., cycler system). See 21 C.F.R. Sec. 876.5630. If the peritoneal dialysate is not pre-
packaged, the US FDA requires the dialysate be prepared from a dialysate concentrate and
“sterile purified water,” which is defined by the FDA in 21 C.F.R. Sec. 165.110(a)(2)(iv) and
(vii). Some possible contaminants present in water used to prepare dialysis fluid can be (i)
particles, (ii) chemicals, and (iii) microbial contaminants such as bacteria, fungi and yeasts, and
microbial derivatives or fragments (e.g., endotoxins released during active growth and lysis of
micro-organisms). In additional to meeting purity and sterility requirements, peritoneal dialysate
must also contain specific and precise amounts of solutes, such as sodium chloride, sodium
bicarbonate, osmotic agents, buffers, and cation infusates.
Because traditional peritoneal dialysis systems require FDA-approved, pre-packaged
dialysate, the dialysate can be expensive due to high manufacturing, shipping, and storage costs.
Shortages can also occur. The problems are not mitigated by on-site dialysate preparation
because the source water must still meet high fluid purity and sterility characteristics. Such
standards may be difficult to meet, particularly for continuous, automatic peritoneal dialysis
machines designed for home use. Further, traditional systems usually require storage of
hundreds of liters of dialysate bags, including 300 L or more of peritoneal dialysate and over
300 kg of fluid per month. Storage and shipping of the peritoneal dialysate is expensive, labor
intensive, and requires significant storage space.
Known systems and methods require significant space to store peritoneal dialysate prior
to use. Continuous ambulatory peritoneal dialysis (CAPD) traditionally uses 1-4 exchanges of
peritoneal dialysate a day, with an overnight dwell. Because each exchange requires
approximately 2-4 L of peritoneal dialysate, use of prepackaged dialysate requires storing about
8-16 L of dialysate per day, or 56-112 L of dialysate per week. Automated peritoneal dialysis
21349709_1:hxa
uses a cycler to cycle peritoneal dialysis into and out of the peritoneal cavity of the patient,
generally at night. APD generally uses 3-5 exchanges daily, requiring up to 20 L of dialysate
per day and up to 140 L of dialysate per week. Tidal Peritoneal Dialysis (TPD) is similar to
APD with the exception that a between 250 mL to 1000 mL of the peritoneal dialysate is left in
the peritoneal cavity of the patient between infusions. The known systems and methods require
significant storage space and can deter the adoption of CAPD, APD, or TPD.
There is a need for systems and methods that can generate and use peritoneal dialysate
using water of varying quality. There is also a need for a system that can generate peritoneal
dialysate and use the peritoneal dialysate with an integrated cycler, reducing the number of
components necessary for peritoneal dialysis. The need includes peritoneal dialysate having
purity and sterility requirements such that patients will not contract an infection due to bacteria
or other pathogens in fluid used for peritoneal dialysate. The need is acute for automated fluid
generation for continuous dialysis machines for use at home where a water source can be tap
water or other non-sterile source. There is also a need for systems and methods that allow for the
automated generation of dialysate suitable for peritoneal dialysis that contains the proper
amounts of solutes and cations. There is further a need for a system that uses filtration, as
opposed to heat, in sterilization of the dialysate, which reduces the generation of glucose
degradation products. There is also a need for a system that can generate peritoneal dialysate on
demand, or for direct infusion into the patient, reducing the storage time and space requirements,
as well as lowering the probability of loss of sterility of the dialysate.
OBJECT OF THE INVENTION
It is an object of the present invention to at least substantially satisfy one or more of the
above needs.
SUMMARY OF THE INVENTION
The first aspect of the invention relates to a purity and control system for use in an
peritoneal dialysis. In any embodiment, the purity and control system can comprise a first fluid
line fluidly connected to a peritoneal dialysate generation system and a first ultrafilter; a second
fluid line fluidly connecting the first ultrafilter to a second ultrafilter; the peritoneal dialysate
generation system comprising at least a water source, an osmotic agent source, an ion
21349709_1:hxa
concentrate source, and a water purification module fluidly connected to a peritoneal dialysate
generation flow path.
In any embodiment, the second ultrafilter can be fluidly connected to a control valve; the
control valve selectively directing fluid to either the peritoneal dialysate generation system or an
integrated cycler.
In any embodiment, the control valve can be fluidly connected to the peritoneal dialysate
generation system at an infusate line.
In any embodiment, the purity control system can comprise a pressure sensor in the first
fluid line.
In any embodiment, the purity control system can comprise a pressure sensor in a third
fluid line fluidly connecting the control valve and the integrated cycler.
In any embodiment, the first ultrafilter can be fluidly connected to a fourth fluid line; the
fourth fluid line fluidly connected to a waste line.
In any embodiment, the waste line can be fluidly connectable to a waste reservoir.
In any embodiment, the waste line can be fluidly connectable to a drain.
In any embodiment, the second ultrafilter can be fluidly connected to a fifth fluid line;
the fifth fluid line fluidly connected to the waste line.
In any embodiment, the fourth fluid line can have a valve positioned between the first
ultrafilter and the waste line; and the fifth fluid line can have a valve positioned between the
second ultrafilter and the waste line.
In any embodiment, the system can comprise a second valve positioned on a third fluid
line fluidly connecting the second ultrafilter to the integrated cycler.
In any embodiment, the system can comprise a control system, the control system
controlling a peritoneal dialysate flow rate based on data from the pressure sensor.
21349709_1:hxa
In any embodiment, the control system can control the peritoneal dialysate flow rate to
maintain a pressure of the peritoneal dialysate between-200 mmHg to 500 mmHg, from -50
mmHg to 100 mmHg, from 0 mmHg to 100 mmHg, from -50 mmHg to 200 mm Hg, from 200
mmHg to 500 mmHg, or from 100 mmHg to 400 mmHg.
In any embodiment, the system can comprise a control system, the control system
controlling a peritoneal dialysate flow rate based on data from the pressure sensor.
In any embodiment, the control system can control the peritoneal dialysate flow rate to
maintain a pressure of the peritoneal dialysate between -200 mmHg to 500 mmHg, from -50
mmHg to 100 mmHg, from 0 mmHg to 100 mmHg, from -50 mmHg to 200 mm Hg, from 200
mmHg to 500 mmHg, or from 100 mmHg to 400 mmHg.
In any embodiment, the water purification module can comprise a sorbent cartridge.
The features disclosed as being part of the first aspect of the invention can be in the first
aspect of the invention, either alone or in combination, or follow a preferred arrangement of one
or more of the described elements.
The second aspect of the invention is directed to a method of delivering peritoneal
dialysate to a patient comprising the steps of generating peritoneal dialysate with a peritoneal
dialysate generation system; pumping the peritoneal dialysate through the purity control system
of the first aspect of the invention; and pumping the peritoneal dialysate from the purity control
system to the peritoneal dialysate cycler and into a peritoneal cavity of a patient.
In any embodiment, the method can comprise the step of measuring a pressure of the
peritoneal dialysate upstream of the first ultrafilter, and adjusting a peritoneal dialysate flow rate
through the purity control system based on the pressure of the peritoneal dialysate.
In any embodiment, the method can comprise the step of measuring a pressure of the
peritoneal dialysate downstream of the second ultrafilter, and adjusting a peritoneal dialysate
flow rate through the purity control system based on the pressure of the peritoneal dialysate.
21349709_1:hxa
In any embodiment, the method can comprise the step of generating an alert if the
pressure of the peritoneal dialysate upstream of the first ultrafilter is outside of a predetermined
range.
In any embodiment, the method can comprise the step of generating an alert if the
pressure of the peritoneal dialysate downstream of the second ultrafilter is outside of a
predetermined range.
The features disclosed as being part of the second aspect of the invention can be in the
second aspect of the invention, either alone or in combination, or follow a preferred arrangement
of one or more of the described elements.
BRIEF DESCRIPTION OF THE DRAWINGS
Preferred embodiments of the present invention will now be described, by way of
example only, with reference to the accompanying drawings, in which:
shows a peritoneal dialysate generation flow path with an integrated cycler.
shows a system for adding concentrates to a peritoneal dialysate generation flow
path.
shows an overview of a system for generating and using peritoneal dialysate with
a single concentrate source.
shows an overview of a system for generating and using peritoneal dialysate with
multiple concentrate sources.
shows an alternative peritoneal dialysate generation flow path with an integrated
cycler.
shows a peritoneal dialysate generation flow path with multiple dispensing
options.
21349709_1:hxa
FIG.’s 7A-D show a peritoneal dialysate generation cabinet with a water reservoir and
waste reservoir.
shows a peritoneal dialysate generation cabinet connected to a faucet and drain.
shows a peritoneal dialysate generation and delivery system.
DETAILED DESCRIPTION OF THE INVENTION
Unless defined otherwise, all technical and scientific terms used have the same meaning
as commonly understood by one of ordinary skill in the art.
The articles “a” and “an” are used to refer to one or to over one (i.e., to at least one) of
the grammatical object of the article. For example, “an element” means one element or over one
element.
The terms “adjusting” or to “adjust” refer to changing a parameter of a fluid, gas, or
system.
The term “around,” when used in the context of parameter values or ranges, means
approximately, or within a certain margin from, the described values or ranges and should be
given the broadest interpretation as understood by those of skill in the art.
The term “comprising” includes, but is not limited to, whatever follows the word
“comprising.” Use of the term indicates the listed elements are required or mandatory but that
other elements are optional and may be present.
The term “consisting of” includes and is limited to whatever follows the phrase
“consisting of.” The phrase indicates the limited elements are required or mandatory and that no
other elements may be present.
The term “consisting essentially of” includes whatever follows the term “consisting
essentially of” and additional elements, structures, acts or features that do not affect the basic
operation of the apparatus, structure or method described.
21349709_1:hxa
The terms “control,” “controlling,” or “controls” refers to the ability of one component
to direct the actions of a second component.
A “control system” can be a combination of components acting together to maintain a
system to a desired set of performance specifications. The control system can use processors,
memory and computer components configured to interoperate to maintain the desired
performance specifications. The control system can also include fluid or gas control
components, and solute control components as known within the art to maintain the
performance specifications.
A “control valve” can be a valve that selectively controls movement of fluid, gas, or
combinations therefore into one or more flow paths, sections, components or sections of a
system.
The term “delivering peritoneal dialysate” or to “deliver peritoneal dialysate” refer to
generating peritoneal dialysate and infusing the peritoneal dialysate. In one non-limiting
example, the infusion can be provided to a patient.
The term “dialysate” can generally refer to any fluid used in dialysis from which solutes
and particles can flow into or out of across a membrane to second fluid. For example, for
peritoneal dialysis, solutes can be diffused through a peritoneal membrane of a patient. Dialysate
can differ depending on the type of dialysis to be carried out. For example, dialysate for
peritoneal dialysis may include different solutes or different concentrations of solutes than
dialysate for hemodialysis.
The term “downstream” refers to a position of a first component in a flow path relative
to a second component wherein fluid, gas, or combinations thereof, will pass by the second
component prior to the first component during normal operation. The first component can be
said to be “downstream” of the second component, while the second component is “upstream”
of the first component.
A “drain” is a conduit for carrying waste fluids or gases.
The term “fluid” can be any substance without a fixed shape that yields easily to external
pressure such as a gas or a liquid. Specifically, the fluid can be water containing any solutes at
21349709_1:hxa
any concentration. The fluid can also be dialysate of any type including fresh, partially used, or
spent.
The terms “fluid connection,” “fluidly connectable,” or “fluidly connected” refer to the
ability to pass fluid, gas, or combinations thereof from one point to another point. The two
points can be within or between any one or more of compartments, modules, systems, and
components, all of any type.
A “fluid line” can refer to a tubing or conduit through which a fluid, gas, or fluid
containing gas can pass. The fluid line can also contain air during different modes of operation
such as cleaning or purging of a line.
To “generate an alert” or “generating an alert” refer to providing a user with an
indication of a state of a system.
The terms to “generate peritoneal dialysate,” “generating peritoneal dialysate,” or
“peritoneal dialysate generation” refers to creating a peritoneal dialysate solution from
constituent parts.
The term “infusate line” refers to a fluid line for carrying peritoneal osmotic agents
and/or cation infusates into a peritoneal dialysate generation flowpath.
An “integrated cycler” can refer a component for movement of fluid into and out of the
peritoneal cavity of a patient, wherein the integrated cycler forms a part of an overall system. In
one non-limiting example, the integrated cycler can be contained in a housing with other
components used for peritoneal dialysis and be in fluid and electrical connection with desired
components.
An “ion concentrate source” refers to a source of one or more ionic compounds. The ion
concentrate source can be in water or solid form. The ion concentrate source can further have
one or more ionic compounds that are at a higher ion concentration greater than generally used
in dialysis.
The term “maintain a pressure” means to control one or more variables to prevent the
pressure from exceeding or dropping below predetermined thresholds.
21349709_1:hxa
The term “measuring” or “to measure” can refer to determining any parameter or
variable. The parameter or variable can relate to any state or value of a system, component,
fluid, gas, or mixtures of one or more gases or fluids.
An “osmotic agent source” refers to a source of osmotic agents in solid and/or solution
form. The osmotic agent source can interface with at least one other module found in systems
for dialysis. The osmotic agent source can contain at least one fluid pathway and include
components such as conduits, valves, filters or fluid connection ports, any of which are fluidly
connectable to each other or to a fluid flow path. The osmotic agent source can either be formed
as a stand-alone enclosure or a compartment integrally formed with an apparatus for dialysis for
containing an osmotic agent source. If the osmotic agent(s) is in solid form, a system as
described in the present invention can deliver a fluid, such as a highly purified or sterile water,
to dilute the solid osmotic agent. Optional mechanical agitation or other means such as stirring
can be used to help dissolve the solid osmotic agent.
The term “peritoneal cavity” refers to the space between the parietal peritoneum and
visceral peritoneum of a patient.
“Peritoneal dialysate” is a dialysis solution to be used in peritoneal dialysis having
specified parameters for purity and sterility. Peritoneal dialysate is not the same as dialysate
used in hemodialysis although peritoneal dialysate may be used in hemodialysis.
The term “peritoneal dialysate flow rate” refers to a rate of a fluid moving through a
specified section of a peritoneal dialysate generation system.
A “peritoneal dialysate generation flow path” can refer to a path used in generating
dialysate suitable for peritoneal dialysis.
A “peritoneal dialysate generation system” refers to a collection of components used to
generate peritoneal dialysate.
“Peritoneal dialysis” is a therapy wherein a dialysate is infused into the peritoneal cavity,
which serves as a natural dialyzer. In general, waste components diffuse from a patient’s
bloodstream across a peritoneal membrane into the dialysis solution via a concentration
gradient. In general, excess fluid in the form of plasma water flows from a patient’s bloodstream
21349709_1:hxa
across a peritoneal membrane into the dialysis solution via an osmotic gradient. Once the
infused peritoneal dialysis solution has captured sufficient amounts of the waste components the
fluid is removed. This cycle can be repeated for several cycles each day or as needed.
The term “predetermined range” is a range of possible values for a parameter to be set
The term “pressure sensor” refers to a device for measuring the pressure of a gas or
liquid in a vessel, container, or fluid line.
The term “pump” refers to any device that causes the movement of fluids or gases by
applying suction or pressure.
The terms “pumping” or to “pump” refer to moving a fluid or gas through a flow path
with a pump.
The term “purity control system” refers to a set of components that can sterilize or purify
a fluid or gas.
“Selectively directing fluid” or to “selectively direct fluid” means to cause a fluid, gas,
or combinations thereof to move in a specified flow path.
The term “sorbent cartridge” refers to a cartridge containing one or more sorbent
materials for removing specific solutes from solution. The term “sorbent cartridge” does not
require the contents in the cartridge be sorbent based, and the contents of the sorbent cartridge
can be any contents capable of removing solutes from a dialysate. The sorbent cartridge may
include any suitable amount of one or more sorbent materials. In certain instances, the term
“sorbent cartridge” refers to a cartridge which includes one or more sorbent materials besides
one or more other materials capable of removing solutes from dialysate. “Sorbent cartridge” can
include configurations where at least some materials in the cartridge do not act by mechanisms
of adsorption or absorption.
An “ultrafilter” can refer to a semi permeable membrane through which a fluid can pass
with removal of one or more solutes or particles from the fluid.
21349709_1:hxa
The term “upstream” refers to a position of a first component in a flow path relative to a
second component, wherein fluid, gas, or a combination thereof, will pass by the first
component prior to the second component during normal operation. The first component can be
said to be “upstream” of the second component, while the second component is “downstream”
of the first component.
A “valve” refers to a device capable of directing the flow of fluid or gas by opening,
closing or obstructing one or more pathways to allow the fluid or gas to travel in a path. One or
more valves configured to accomplish a desired flow can be configured into a “valve assembly.”
The term “waste line” refers to a fluid line through which waste fluids, gases, or spent
dialysate can be pumped.
A “waste reservoir” can refer to a container for collecting and storing used or waste
fluids.
The term “water purification module” refers to a component or collection of components
capable of removing biological or chemical contaminants from water.
The term “water source” refers to a source from which water can be obtained. In one
non-limiting embodiment, the obtained water is potable.
Peritoneal Dialysis Purity Control System
The invention relates to systems and methods for generating and using peritoneal
dialysate in peritoneal dialysis. A system for generating peritoneal dialysate and delivering
peritoneal dialysis therapy to a patient 134 can be configured as illustrated in The
system includes a peritoneal dialysate generation flow path 101. Fluid from a water source,
such as water tank 102, can be pumped into the peritoneal dialysate generation flow path 101.
Additionally, or as an alternative to a water tank 102, the system can use a direct connection 112
to a water source. System pump 108 can control the movement of fluid through the peritoneal
dialysate generation flow path 101. If a direct connection 112 to a water source is used, a
pressure regulator 113 ensures the incoming water pressure is within a predetermined range.
The system pumps the fluid from water source through a water purification module 103 to
remove chemical contaminants in the fluid in preparation for creating dialysate.
21349709_1:hxa
The water source can be a source of potable water including a purified water source.
Purified water can refer to any source of water treated to remove at least some biological or
chemical contaminants. The water tank 102 can alternatively be a non-purified water source,
such as tap water, wherein the water from the water tank 102 can be purified by the system as
described. A non-purified water source can provide water that has undergone no additional
purification, water that has undergone some level of purification, but does not meet the
definition of “purified water” provided, such as bottled water or filtered water. The peritoneal
dialysate generation flow path 101 can also have a direct connection 112 to a purified or non-
purified water source, shown as direct connection 112. The water source can be any source of
water, whether from a tap, faucet, or a separate container or reservoir.
The water purification module 103 can be a sorbent cartridge. The sorbent cartridge can
include aluminum oxide for removal of fluoride and heavy metals. The sorbent cartridge can
have a first layer of aluminum oxide, a second layer of activated carbon and a third layer of an
ion exchange resin. The sorbent cartridge can be sized depending on the needs of the user, with
a larger sized sorbent cartridge allowing for more exchanges before the sorbent cartridge must
be replaced. The sorbent cartridge can also include activated carbon. The activated carbon
operates to adsorb non-ionic molecules, organic molecules, and chlorine from the water, along
with some endotoxins or bacterial contaminants. In certain embodiments, the sorbent cartridge
can include activated carbon, activated alumina, and potentially other components that work
primarily by physical and chemical adsorption, combined with one or more ion exchange
materials. The ion exchange materials can be any known material in the art, but preferably the
ion exchange materials will release hydrogen and hydroxyl ions in exchange for other cations
and anions in solution, resulting in water formation by the exchange process.
The sorbent cartridge can additionally include a microbial filter and/or a particulate
filter. A microbial filter can further reduce the amount of bacterial contaminants present in the
fluid from the water tank 102 or direct connection 112. Optionally, an ultrafilter can be
included to remove endotoxins from the fluid. A particulate filter can remove particulate matter
from the fluid. The water tank 102 can be any size usable with the system, including between
around 12 and around 25 L. A water tank 102 of 20 L can generally generate the necessary
peritoneal dialysate for multiple cycles. In certain embodiments, the water purification module
103 can include an optional UV light source for further purification and sterilization of the water
prior to adding osmotic agents or ion concentrates.
21349709_1:hxa
Alternatively, the water purification module 103 can be any component capable of
removing contaminants from the water in the water source, including any one or more of a
sorbent cartridge, reverse osmosis module, nanofilter, combination of cation and anion exchange
materials, activated carbon, activated alumina, silica, or silica based columns.
After the fluid passes through the water purification module 103, the fluid is pumped to a
concentrate source 104, where necessary components for carrying out peritoneal dialysis can be
added from the concentrate source 104. The concentrates in the concentrate source 104 are
utilized to create a peritoneal dialysis fluid that matches a dialysis prescription. Concentrate
pump 105 and concentrate valve 111 can control the movement of concentrates from the
concentrate source 104 to the peritoneal dialysate generation flow path 101 in a controlled
addition. Concentrate valve 111 can be replaced with a hose T. A hose T is a fluid connector in
a T-shape, with a port at each end for fluid to enter or exit the hose T. The concentrates added
from the concentrate source 104 to the peritoneal dialysate generation flow path 101 can include
any component prescribed for use in peritoneal dialysate. Table 1 provides non-limiting
exemplary ranges of commonly used components of peritoneal dialysate.
Table 1
Component Concentration
Sodium chloride 132-134 mmol/L
Calcium chloride dehydrate 1.25-1.75 mmol/L
Magnesium chloride hexahydrate 0.25-0.75 mmol/L
Sodium Lactate 35-40 mmol/L
Dextrose (D-glucose) monohydrate 0.55-4.25 g/dL
pH 5-6
Osmolality 346-485 (hypertonic)
To reduce the glucose degradation products (GDP) formed, some peritoneal dialysate
systems use a low GDP formulation. Exemplary peritoneal dialysate concentrations for low
GDP formulations are provided in Table 2. Generally, the low GDP peritoneal dialysate is
provided in two separate bags, with one bag containing calcium chloride, magnesium chloride
and glucose maintained at low pH, and the second bag containing sodium chloride and the
21349709_1:hxa
buffer components, including sodium lactate and sodium bicarbonate. The two bags are mixed
prior to use to generate a peritoneal dialysate with a neutral pH. Alternatively, a two chamber
bag can be used to prevent mixing of fluids prior to use wherein, the chambers, can for example,
be separated by a wall of a divider of any type.
Table 2
Low GDP peritoneal dialysate formulations
Component Concentration
Sodium 132-134 mEq/L
Calcium 2.5-3.5 mEq/L
Magnesium 0.5-1.0 mEq/L
Lactate 0-40 mEq/L
Bicarbonate 0-34 mEq/L
pH 6.3-7.4
% glucose (g/dL) 1.5-4.25
One of skill in the art will understand that other components can be used in place of the
components listed in Tables 1-2. For example, dextrose as listed in Table 1 is commonly used as
an osmotic agent. However, other osmotic agents can be used in addition to, or in place of, the
dextrose, including glucose, icodextrin or amino acids, including dialysate with multiple osmotic
agents. Although the sources of sodium, calcium, and magnesium listed in Table 1 are chloride
salts, other sodium, magnesium, and calcium salts can be used, such as lactate or acetate salts.
Peritoneal dialysate may also contain buffers for maintaining pH of the peritoneal dialysate,
including bicarbonate buffer, acetate buffer, or lactate buffer. Although not generally used in
peritoneal dialysis, potassium chloride can be used for hypokalemic patients who don’t receive
sufficient potassium through diet. The concentrate source 104 can contain one or more osmotic
agents, as well as one or more ion concentrates, such as concentrated sodium chloride, sodium
lactate, magnesium chloride, calcium chloride, and/or sodium bicarbonate. The concentrate
source 104 can be a single source of concentrates, including both osmotic agents and ion
concentrates, or can include multiple sources of concentrates, with separate sources for the
osmotic agents and ion concentrates. The system can have a single concentrate that has all
components mixed for a daytime or overnight treatment for use in a home by a single patient.
21349709_1:hxa
Alternatively, the concentrate source 104 can include separate sources for any solutes to be used
in the peritoneal dialysate each with a separate concentrate pump to add each solute. Concentrate
pump 105 pumps concentrated solutions from the concentrate source or sources 104 to the
peritoneal dialysate generation flow path 101 in a controlled addition. Where more than one
concentrate source is used, separate concentrate pumps can move each of the concentrates into the
peritoneal dialysate generation flow path 101, or a single concentrate pump can be used, with
valves configured allow individual control over the movement of each of the concentrate
solutions to the peritoneal dialysate generation flow path 101.
After addition of solutes from the concentrate source 104, the fluid in the peritoneal
dialysate generation flow path 101 can contain all the necessary solutes for peritoneal dialysis.
The peritoneal dialysate should reach a level of sterility for peritoneal dialysis. The level of
sterility can be any level that meets an applicable regulatory requirement, such as a sterility
assurance level of 10-6 required by the FDA, meaning that the chance a viable organism is
present after sterilization is 1 in 1,000,000. The system can pump the fluid to a sterilization
module for sterilization of the peritoneal dialysate. As shown in the sterilization module
can include one or more of a first ultrafilter 107, a second ultrafilter 109, and an optional UV
light source 106. The sterilization module can be any component or set of components capable
of sterilizing the peritoneal dialysate. The sterilization module can be comprised of a single or
multiple ultrafilters. The number of ultrafilters can vary from one, two, three, four, and more
depending on configuration and usage. A secondary component, such as a UV light source 106
or microbial filter (not shown), can be used in the sterilization module to provide additional
sterilization of the peritoneal dialysate. The sterilization module can also include at least two
ultrafilters, including second ultrafilter 109 for further sterilization of the fluid and redundancy
of the system to protect against sterilization failure. The UV light source 106 can be positioned
at any location in the peritoneal dialysate generation flow path 101, including upstream of
ultrafilter 107, between ultrafilters 107 and 109 or downstream of ultrafilter 109. The
ultrafilters 107 and 109 used in the sterilization module can be replaced as necessary. In one
non-limiting embodiment, the ultrafilters 107 and 109 can have a 3-6 month lifetime before
replacement. However, no limitation on the lifespan of the ultrafilters is imposed by the system.
The ultrafilters 107 and 109 can be any ultrafilter known in the art capable of sterilizing the
peritoneal dialysate. A non-limiting example of an ultrafilter is the hollow fiber ForClean
ultrafilter, available from Bellco, Mirandola (MO), Italy. In certain embodiments, the
sterilization module 106 can use heat sterilization. The sterilization module can include a heater
21349709_1:hxa
(not shown) to heat the prepared dialysate. Alternatively or additionally, the sterilization
module can include a flash pasteurization module (not shown) to sterilize the dialysate through
flash pasteurization. The sterilization module can include both heat-based sterilization
components and filtration based sterilization components, with a processor, controller, or the
user adjusting the mode of sterilization based on the mode of use. For example, a heat based
sterilization can be used when the peritoneal dialysate is generated for later use, while a
filtration based sterilization can be used when the peritoneal dialysate is generated for
immediate use.
The generated peritoneal dialysate can be pumped directly to an integrated cycler 110 for
immediate infusion into a patient 134. Alternatively, the dialysate can be pumped to an optional
dialysate container 114 as a pre-prepared bolus of solution for storage until ready for use by a
patient 134. Valve 116 can control the movement of fluid to either the integrated cycler 110 or
the dialysate container 114. Stored dialysate in dialysate container 114 can be pumped as
needed to the integrated cycler 110 by pump 115 through valve 117. The dialysate container
114 can include one or more sterilized dialysate bags. The dialysate bags, once filled with
peritoneal dialysate, can be stored until needed by the patient 134. The dialysate container 114
can alternatively be a reusable sterilized container or bag. The reusable container or bag can be
cleaned and sterilized daily, or at set time periods. Alternatively, the dialysate container 114 can
be any type of storage container, such as a stainless-steel container. The dialysate container
114 can store enough peritoneal dialysate for a single infusion cycle of peritoneal dialysate into
the patient 134, or enough peritoneal dialysate for multiple infusions into a patient 134.
Additional or alternative storage containers can be included at other locations in the peritoneal
dialysate generation flow path 101. A storage container can be included upstream of the
sterilization module, and downstream of the water purification module 103. Before the fluid is
utilized in the cycler stage, the fluid can be pumped through the sterilization module to ensure
sterility of stored fluid. Further, concentrates can be added to fluid before storing the fluid, or
after storage of the fluid but prior to sterilization in the sterilization module.
The storage containers can be either upstream or downstream of the concentrate source
104. The addition of concentrates to the fluid can happen either before storage of the fluid, or
after storage of the fluid just before sterilization in the sterilization module.
21349709_1:hxa
By generating and immediately using the peritoneal dialysate, the dialysate storage time
can be reduced, reducing the possibility of bacterial growth. A user interface can be included on
the peritoneal dialysis generation machine in communication with the control system, allowing a
patient 134 to direct the generation of peritoneal dialysate at a selected time as needed.
Additionally, or alternatively, the peritoneal dialysate machine can include a timer, and the timer
can cause the peritoneal dialysate machine to generate peritoneal dialysate at predetermined
times according to the patient’s 134 peritoneal dialysis schedule. Alternatively, the peritoneal
dialysate generation machine can be equipped with wireless communication, such as Wi-Fi,
Bluetooth, Ethernet, or any other wireless communication system known in the art. The user can
direct the peritoneal dialysis machine to generate peritoneal dialysate at a specified time from
any location. By using a timer, user interface, or wireless communication to control the
generation of peritoneal dialysate on demand, the peritoneal dialysate storage time can be
reduced, lowering the chances of generating significant amounts of degradation products or
allowing bacterial growth.
The peritoneal dialysate can be generated and used in real time, with direct infusion of
the peritoneal dialysate into the patient 134 through the integrated cycler 110. For real time
generation and use of the peritoneal dialysate, the flow rate of fluid through the peritoneal
dialysate generation flow path 101 can be between 50 and 300 ml/min. With the online
generation of fluid described, a flow rate of 300 ml/min can support an exchange time of
between 10 and 15 minutes for a full cycle of draining and filling the peritoneal cavity of a
patient 134. If a dialysate container 114 is used to store generated peritoneal dialysate, the flow
rate of fluid through the peritoneal dialysate generation flow path 101 can be any flow rate
capable of producing the necessary peritoneal dialysate. In certain embodiments, the flow rate
can be at least around 15 mL/min, which can produce around 20 L of peritoneal dialysate in 24
hrs. The integrated cycler 110 can then infuse the generated peritoneal dialysate into the
peritoneal cavity of a patient 134. The integrated cycler 110 and the rest of the system can
communicate for the purposes of generation and use of the peritoneal dialysate by any method
known in the art, including Bluetooth, Wi-Fi, Ethernet, or direct hardware connections to meet
patient or clinic needs. Additional valves and regulators (not shown in can be included
to aid in connection and operation of the peritoneal dialysate generation flow path 101 and
integrated cycler 110. The integrated cycler 110 and the peritoneal dialysate generation flow
path 101 can communicate directly, or can each communicate with a control system for control
over the generation and use of the peritoneal dialysate.
21349709_1:hxa
In certain embodiments, the dialysate container 114 can store enough peritoneal
dialysate for multiple infusions into the patient 134, including enough peritoneal dialysate for
one day or more of treatment. A timer can be included in the control system and can cause the
machine to generate fresh peritoneal dialysate each day or at set times.
The integrated cycler 110 can include a metering pump 119 for metering peritoneal
dialysate into the peritoneal cavity of the patient 134. An in-line heater 118 heats the peritoneal
dialysate to a desired temperature prior to infusion into the patient 134. A pressure regulator
120 ensures the peritoneal dialysate pressure is within a predetermined range safe and
comfortable for infusion into the patient 134. The metering pump 119 can use any safe pressure
for infusing fluid into the patient 134. Generally, the pump pressures are on average set at ±10.3
kPa or 77.6 mmHg. If there is no fluid flow, the maximum pressure can increase to ±15.2 kPa
or 113.8 mmHg for a short period, such as less than 10 seconds. The peritoneal dialysate is
infused into the peritoneal cavity of the patient 134 through infusion line 124. An additional
microbial filter (not shown) may be used to sterilize the peritoneal dialysis fluid immediately
before the peritoneal dialysate enters the patient 134. After a dwell period, the peritoneal
dialysate is drained from the patient 134 through drain line 123. Pump 122 provides a driving
force for removing the peritoneal dialysate from the patient 134. Treatment, other than the first
full cycle for a patient in APD, generally begins with drainage of the peritoneal cavity of the
patient 134, prior to infusing the fresh peritoneal dialysate into the patient 134. An optional
waste reservoir 121 can be included to store the used peritoneal dialysate for disposal.
Alternatively, the drain line 123 can be directly connected to a drain for direct disposal. A
standard waste reservoir 121 is 15 L, however, the waste reservoir 121 can be any size,
including between 12 and 20 L. For patients requiring a higher drainage, a drain manifold can
be included for connecting multiple waste reservoirs. There is no set rate for draining of
peritoneal dialysate from the peritoneal cavity of the patient 134, and any flow rate can be used
with the integrated cycler 110.
Various sensors positioned in the peritoneal dialysate generation and infusion system
ensure that the generated fluid is within predetermined parameters. Flow meter 135 ensures the
incoming water is at a correct flow rate, while pressure sensor 136 ensures the incoming water is
at an appropriate pressure. Conductivity sensor 125 is used to ensure that the water exiting
water purification module 103 has been purified to a level safe for use in peritoneal dialysis.
Conductivity sensor 126 ensures the conductivity of the dialysate after the addition of
21349709_1:hxa
concentrates from concentrate source 104 is within a predetermined range. Refractive index
sensor 127 ensures that the concentration of the osmotic agents is within a predetermined range.
pH sensor 128 ensures the pH of the peritoneal dialysate is within a predetermined range. After
passing through the sterilization module including second ultrafilter 109, pH sensor 129 and
conductivity sensor 130 are used to ensure that no changes in the pH or conductivity have
occurred during purification or storage of the dialysate in dialysate container 114. The
integrated cycler 110 has flow meter 131, pressure sensor 132 and temperature sensor 133 to
ensure that the dialysate being infused into the patient 134 is within a proper flow rate, pressure,
and temperature range. The flow meter 131 can also calculate the volume of solution infused
into the patient 134. The pressure sensor 132 can monitor the pressure in the peritoneal cavity.
Overfill, or excessive solution in the peritoneal cavity beyond the target volume may
present complications in therapy. Overfill can be caused by many factors, including failing to
fully drain the peritoneal cavity prior to infusion of fresh peritoneal dialysate. In any
embodiment, the integrated cycler 110 can start therapy with a drain step to ensure that no
peritoneal dialysate remains in the peritoneal cavity. Monitoring both pressure and volume of
peritoneal dialysate introduced to the patient 134 can avoid overfill. If the pressure rises to a
certain point, the system can be programmed to end filling or send an alert to a user to complete
filling of the peritoneal cavity at a desired level. The volume of peritoneal dialysate extracted
from and introduced to the patient 134 can also be monitored with flow meters to ensure proper
volumes of exchanges. Draining the peritoneal cavity can be performed in a similar manner by
monitoring the pressure and volume of the drained peritoneal dialysate.
As illustrated in the necessary solutes can be added to the peritoneal dialysate
generation flow path 101 from a single concentrate source 104. The solutes can be present in
concentrated from within the concentrate source 104 in a fixed ratio for peritoneal dialysis, as
shown in Table 1. Using a single concentrate source 104 for all solutes results in peritoneal
dialysate having a fixed ratio of each of the solutes.
Table 3 provides exemplary non-limiting ranges of solutes that can be added from a
single concentrate source 104 to the peritoneal dialysate generation flow path 101, including the
starting concentration of the solutes in the concentrate source, as well as exemplary final
volumes of the solutes in the dialysate and the exemplary flow rates of both the solutes and the
water in the peritoneal dialysate generation flow path 101 that will achieve those concentrations.
21349709_1:hxa
The solutes shown in Table 3 are traditional peritoneal dialysate solutes. Table 4 shows
exemplary ranges of solutes that can be used as a low GDP formulation. Table 5 shows
exemplary ranges of solutes that can be used with icodextrin as the osmotic agent. Icodextrin is
sometimes used as an osmotic agent for a long dwell period. If dextrose or glucose is used in a
long dwell period, reabsorption of the ultrafiltrate can occur, reducing the net volume of fluid
removed. Icodextrin can result in a long sustained ultrafiltration, and can provide improved
ultrafiltration efficiency over a long dwell period. One of skill in the art will understand that the
concentrations of any of the solutes shown in Tables 3-5 can be altered by altering the flow rates
of the system pump 108 or concentrate pump 105. However, the ratio of the solutes included is
fixed if using a single concentrate source 104. If the ratio of the solutes needs to be altered for
any reason, a new concentrate solution may be needed.
Table 3
Exemplary solutes for addition from a single concentrate source
Solution volume Flow rate
Component Concentration (g/l) (ml/L) (ml/min)
Glucose 100 – 850 50-400 1 - 18
Sodium Chloride 13 – 108 50-400 1 - 18
Sodium Lactate 11 – 90 50-400 1 - 18
MgCl .6H O 0.13 - 1.02 50-400 1 - 18
CaCl .2H O 0.6 - 5.1 50-400 1 - 18
Water 600-950 50-1000
21349709_1:hxa
Table 4
Exemplary solute ranges in a low GDP solution
Solution volume Flow rate
Component Concentration (g/l) (ml/L) (ml/min)
Glucose 100 - 900 50-400 1 – 18
Sodium Chloride 13 - 108 50-400 1 – 18
Sodium Lactate 11 - 90 50-400 1 – 18
MgCl .6H O 0.13 - 1.02 50-400 1 – 18
CaCl .2H O 0.6 - 5.1 50-400 1 – 18
Water 600-950 50-1000
Table 5
Exemplary solute ranges in icodextrin solution
Solution volume Flow rate
Component Concentration (g/l) (ml/L) (ml/min)
Icodextrin 100 – 850 100-400 2-37
Sodium Chloride 13 - 108 100-400 1 – 18
Sodium Lactate 11 - 90 100-400 2-37
MgCl .6H O 0.13 - 1.02 100-400 2-37
CaCl .2H O 0.6 - 5.1 100-400 2-37
Water 600-900 50-1000
Although using a single concentrate source 104 in the system requires a fixed ratio of
solutes in the generated peritoneal dialysate, a single concentrate source 104 provides certain
advantages. Storage requirements are decreased, as only a single concentrate solution needs to
be stored for a given dialysate prescription. There is also a lower risk of patient error in adding
solutes to the dialysate in the proper amounts. A single concentrate source 104 also requires less
supplies, less pumps, and less hardware. Further, because fewer containers are needed, the
containers are easier to manage, clean, and disinfect. A higher concentration of solutes in the
concentrate source 104 will allow minimization of the container size and maximization of the
21349709_1:hxa
source water used in PD solution preparation, lowering costs. The limiting factor is mutual
solubility of the components, which is generally limited by glucose or icodextrin solubility. The
flow rate for the source water can be optimized to adjust the time required to prepare the
solution. In the case of on-demand dialysate preparation, a high flow rate is desired to minimize
the time needed to prepare the solution. The flow rate limit will be controlled by the metering
accuracy of the concentrate pump 105 at the rate required to match the water feed. With a single
concentrate source 104, about 150 ml/exchange can be needed, which corresponds to about 600
ml/day or 4.2 L/week. The concentrate source 104 can be sized depending on the needs of the
user, with a larger concentrate source requiring less frequent refilling.
The system can also include an additional waste reservoir (not shown in to
collect any waste fluid generated by the water purification module 103 or other components.
Alternatively, waste reservoir 121 can also be used to collect any waste fluid generated by the
water purification module 103 or other components. The waste reservoir collects effluent
generated during disinfection and/or effluent generated by the purification modules, such as a
reverse osmosis system.
The peritoneal dialysate generation flow path 101 and integrated cycler 110 can be
disinfected with a disinfection solution through on-board disinfection if the components of the
peritoneal dialysate generation flow path 101 and integrated cycler 110 are to be reused.
Disinfection may not be required with a fully disposable peritoneal dialysate generation flow
path 101. The peritoneal dialysate generation flow path 101 and integrated cycler 110 can be
configured to form a loop by connecting the portion of the peritoneal dialysate generation flow
path 101 that connects to water tank 102 or the direct connection 112 to a water source to the
infusion line 124. The disinfection solution can be introduced into the peritoneal dialysate
generation flow path 101 and recirculated through the fluid lines by system pumps 108 and 119.
Alternatively, the peritoneal dialysate generation flow path 101 and integrated cycler 110 can be
disinfected separately after disconnection of the integrated cycler 110 from the peritoneal
dialysate generation flow path 101. The disinfection solution can be a citric acid solution, a
peracetic acid solution, a bleach solution, or any other disinfection solution known in the art.
Disinfectant can be circulated through the flow loop and heated. The disinfectant can be heated
to any temperature capable of disinfecting the system, including temperatures of at least 80 °C
or greater. The disinfectant can be introduced to the flow loop and recirculated at elevated
temperatures to ensure complete disinfection.
21349709_1:hxa
Solutes can be added to the peritoneal dialysate generation flow path 201 from two or
more separate concentrate sources, as shown in The peritoneal dialysate generation flow
path 201 can be fluidly connected to a water source and a water purification module upstream of
the concentrate sources 202-206, and a sterilization module, an integrated cycler, and optionally
a dialysate container downstream of the concentrate sources 202-206, as illustrated in
For clarity, these components have been omitted from
As illustrated in the concentrate sources 202-206 can include one or more ion
concentrate sources, such as sodium chloride source 202 containing sodium chloride to be added
in a controlled addition to the peritoneal dialysate generation flow path 201 by concentrate
pump 207 through valve 212, sodium lactate source 203 containing sodium lactate to be added
in a controlled addition to the peritoneal dialysate generation flow path 201 by concentrate
pump 208 through valve 213, magnesium chloride source 204 containing magnesium chloride to
be added in a controlled addition to the peritoneal dialysate generation flow path 201 by
concentrate pump 209 through valve 214, and calcium chloride source 205 containing calcium
chloride to be added in a controlled addition to the peritoneal dialysate generation flow path 201
by concentrate pump 210 through valve 215. One of skill in the art will understand that other
ions can be used in formulation of peritoneal dialysate, and each can be contained in a separate
ion concentrate source or combined into one or more combined ion concentrate sources. The
concentrate source also includes one or more osmotic agent sources, such as dextrose source 206
containing dextrose to be added to the peritoneal dialysate generation flow path 201 by
concentrate pump 211 through valve 216. Any of the concentrate pumps can include flow
meters to control the addition of the solutes. A glucose source and/or an icodextrin source can be
used in addition to, or in place of, dextrose source 206. Multiple osmotic agents can be added to
the peritoneal dialysate generation flow path 201 from one or more osmotic agent sources. One
of skill in the art will understand other solutes can be used alternatively to, or in addition to, the
solutes illustrated in A control system in electronic communication with each of the
concentrate pumps can control the movement of fluid from the concentrate sources to the
peritoneal dialysate generation flow path 201. The amount of each of the concentrates moved
into the peritoneal dialysate generation flow path 201 can be controlled to result in peritoneal
dialysate having a prescribed solute concentration, as determined by a doctor or health care
provider. The valves 212-216 can optionally be replaced with hose T junctions with additional
components for preventing backflow into the concentrate source line if that particular line is not
being used. Optional sensors 217, 218, 219, and 220 ensure the solute concentration in the
21349709_1:hxa
dialysate is at the correct level after each addition. The sensors 217-220 can be any type of
sensor appropriate to confirm delivery of the concentrate, such as conductivity sensors.
Optional pH sensor 221 can ensure that the pH is a proper level after addition of sodium lactate
or other buffer. Optional refractive index meter 222 ensures the dextrose concentration in the
dialysate is at the prescribed level. An additional sensor can be included upstream of sodium
chloride source 202 for sensing the conductivity of the water prior to addition of concentrates.
One of skill in the art will understand that additional sensor arrangements can be used in the
described system. Any number of sensors can be included to monitor the peritoneal dialysate
concentration, including 1, 2, 3, 4, 5, 6, 7, or more sensors. The concentrate sources can contain
the solutes in either solid, powdered, or solution form. A solid or powdered source of solutes
can be dissolved by the system by drawing fluid from the peritoneal dialysate generation flow
path 201 into the concentrate source to generate a solution with a known concentration, such as
a saturated solution of the solutes. During the process of dissolution of the solutes, mechanical,
vibration, heating, or other forms of assistance may be used to dissolve the solid or powder
solutes. The resulting solution is added to the peritoneal dialysate generation flow path as
explained.
Although shown as a refractive index meter 222 in one of skill in the art will
understand that alternative methods of measuring the osmotic agent concentration can be used,
including enzyme based sensors or pulsed amperometric detection. Although illustrated as a
single concentrate source in and five separate concentrate sources in one of skill
in the art will understand that any number of concentrate sources can generate the peritoneal
dialysate, including 1, 2, 3, 4, 5, 6, 7, or more concentrate sources. Any two or more of the
separate concentrate sources illustrated in can be combined into a single solute source,
such as by combining all or some of the ion concentrate sources into a single ion concentrate
source where the mixed contents do not cause precipitation of the mixed concentrates.
Although each concentrate source is illustrated in with a separate concentrate
pump and fluid line, one of skill in the art will understand that more than one concentrate source
can use a single pump and fluid line, with valves arranged thereon for controlled addition to the
peritoneal dialysate generation flow path 201.
The concentrate sources 202-206 can be single use concentrate sources or disposable
concentrate sources. The disposable concentrate sources are used in a single peritoneal dialysate
21349709_1:hxa
generation process and then disposed. Multiple use concentrate sources are used repeatedly, and
refilled as necessary with the solute.
Table 6 provides exemplary, non-limiting, ranges of solutes that can be added to the
peritoneal dialysate using a separate osmotic agent source, glucose in Table 6, and a separate ion
concentrate source containing sodium chloride, sodium lactate, magnesium chloride, calcium
chloride and sodium bicarbonate. Because the glucose is added separately from the ion
concentrates, the ratio of glucose to the other solutes can be varied depending on the needs of
the patient.
Table 6
Exemplary ranges of solutes in a two-concentrate source system
Solution volume Dialysate
Component Concentration (g/l) (ml/L) composition
Part A
Glucose 850 6 - 53 0.55-4.5 g/dL
Part B
NaCl 269 20 92 mmol/L
Sodium Lactate 84 20 15 mmol/L
MgCl .6H O 5 20 0.5 mmol/L
CaCl .2H O 18 20 2.5 mmol/L
NaHCO 105 20 25 mmol/L
Water 927-979 56.10
By using multiple concentrate sources, greater individualization and therapy
customization can be achieved for each patient. With a single concentrate source, all solutes in
the generated peritoneal dialysate must be present in a fixed ratio. By using more than one
concentrate source, the ratio of solutes used in the peritoneal dialysate can be altered as the
concentration of each of the osmotic agent and ion solutes can be individually controlled. For
example, as illustrated by Table 6, with a single ion concentrate source and a single osmotic
agent source, peritoneal dialysate with greater or less osmotic agent per concentration of ions
can be generated, providing the ability to adjust the tonicity of the peritoneal dialysate solution
21349709_1:hxa
independently of the electrolyte composition to meet the UF needs of any patient with a single
set of solutions and allowing greater control over ultrafiltration. The ultrafiltration rate that
results from using the peritoneal dialysate solutions can be altered by altering the concentration
of the osmotic agent independently of the ionic solutes, or by changing the osmotic agent used.
Because the system is not limited to discrete glucose or other osmotic agent concentrations like
known commercial solutions; the system can customize the peritoneal dialysate solutions to
meet the ultrafiltration needs of patient as determined by a healthcare provider. As illustrated in
Table 6, the glucose level in the peritoneal dialysate solution can be varied from 0.55 g/dL to 4.5
g/dL, while maintaining the electrolytes and buffer components constant, allowing the system to
cover the range of glucose formulations currently offered commercially using a single Part A
and Part B composition.
In certain embodiments, two osmotic agent sources can be used, such as a dextrose
source and an icodextrin source. With two osmotic agent sources, one could use dextrose during
the daytime exchanges for CAPD and icodextrin during the night dwell to take advantage of the
higher UF removal from icodextrin. Conversely, dextrose could be used during the night dwell
and icodextrin for the extended daytime dwell in APD systems.
By using separate concentrate sources for each solute, complete individualization of the
concentrations and ratios of solutes in the peritoneal dialysate can be achieved. Table 7
provides exemplary ranges of solutes that can be used in peritoneal dialysate as made by a
system with each solute in a separate concentrate source. An advantage of using separate
concentrate sources for each solute is that virtually any peritoneal dialysate solution composition
can be prepared from a single set of component formulations. A system with separate
concentrate sources for each solute is useful for patients whose prescriptions change periodically
due to diet or other factors. Such patients would need to store multiple formulations if using
only one or two concentrate sources, and the risk of errors would be increased.
21349709_1:hxa
Table 7
Exemplary dialysate composition from a multi-source system
Concentration Solution volume Dialysate
Component (g/l) (ml/L) composition
Part A: Glucose 850 6 – 53 0.55-4.5 g/dL
Part B: NaCl 320 15-18 132-134 mmol/L
Part C: Na Lactate 1000 2-4 15-40 mmol/L
Part D: MgCl2.6H2O 500 0.2-0.4 0.5 -1.0 mmol/L
Part E: CaCl2.2H2O 700 0.5-1.0 2.5-3.5 mmol/L
Part F: NaHCO3 85 0-34 0-34 mmol/L
Part G: Icodextrin 1000 0-75 0-7.5 g/dL
Water 820-971
The one or more concentrate sources can be detachable from the rest of the system for
sterilization. The concentrate sources can also be sterilized each time the concentrate sources
are filled with new concentrate solutions. Further, the concentrate sources can be sterilized after
a set number of uses, or after a set period of time. Moreover, the concentrate sources and the
remaining components including the fluid lines of the peritoneal dialysate generation system can
be sterilized without any of the components by passing a disinfection solution, such as a citric
acid, peracetic acid, or bleach solution, through all of the lines and containers of the system.
illustrates an overview of generating peritoneal dialysate in accordance with the
invention. Water from a water source 301 can be purified by a water purification module 302,
as explained. Concentrates from a single concentrate source 303, which can contain both ion
concentrates and one or more osmotic agents, can be added to the purified water to generate a
non-sterile peritoneal dialysate solution 304. The non-sterile peritoneal dialysate solution 304 is
sterilized by a sterilization module 305, which may include an ultrafilter (not shown). As
explained, the peritoneal dialysate can be further purified by additional components in the
sterilization module 306, such as by ultrafiltration with a second ultrafilter, by a microbial filter,
or by an optional UV light source, to generate a sterilized peritoneal dialysate 307. The
sterilized peritoneal dialysate 307 can be stored or used by any method described herein,
21349709_1:hxa
including by immediately infusing the peritoneal dialysate into a patient 308, or dispensing the
peritoneal dialysate into a dialysate container for later use in peritoneal dialysis 309, as
illustrated in
illustrates an overview of generating peritoneal dialysate with multiple
concentrate sources. Water from a water source 401 can be purified by a water purification
module 402, as explained. Concentrates from an ion concentrate source 403, which can contain
sodium, magnesium, calcium, and bicarbonate, as well as any other ions to be used in peritoneal
dialysis, can be added to the purified fluid. An osmotic agent, such as dextrose, can be added
from a first osmotic agent concentrate source 404. A second osmotic agent, such as icodextrin,
can be added from a second osmotic agent concentrate source 405. As illustrated in any
number of concentrate sources can be used for further individualization of the peritoneal
dialysate, including separate sources for each of the ions used. After addition of the ion and
osmotic agent concentrates, the fluid contains all necessary components for use in peritoneal
dialysis as non-sterilized peritoneal dialysate 406. The non-sterile peritoneal dialysate 406 can
be sterilized by a sterilization module 407, which can include an ultrafilter or other sterilization
components. The peritoneal dialysate can be further sterilized by the sterilization module 408,
either by ultrafiltration with a second ultrafilter, a microbial filter, or further sterilized with an
optional UV light source, to generate a sterilized peritoneal dialysate 409. The sterilized
peritoneal dialysate 409 can be stored or used by any method described herein, including by
immediately infusing the peritoneal dialysate into a patient 410, or dispensing the peritoneal
dialysate into a dialysate container for later use in peritoneal dialysis 411, as illustrated in FIG.
illustrates an alternative peritoneal dialysate generation flow path 501 with an
integrated cycler 539. Water from a water source 502 can be pumped through filter 503 by
system pump 504. The filter 503 can remove any particulate matter from the water prior to
entering the peritoneal dialysate generation flow path 501. The water is then pumped through a
water purification module, illustrated as a sorbent cartridge 506 in As described, the
water purification module can alternatively or additionally include activated carbon, a reverse
osmosis module, a carbon filter, an ion exchange resin, and/or a nanofilter. The water enters the
sorbent cartridge 506 through sorbent cartridge inlet 507 and exits through sorbent cartridge
outlet 508. Pressure sensor 505 measures the pressure across sorbent cartridge 506. Filter 509
removes any particulate matter in the fluid after exiting sorbent cartridge 506. A conductivity
21349709_1:hxa
sensor 510 determines the conductivity of the fluid exiting sorbent cartridge 506 to ensure the
water has been purified. To generate the peritoneal dialysate, concentrates are added from
concentrate source 513 through concentrate connector 514 by concentrate pump 515. Although
shown as a single concentrate source 513 in concentrates can be added from any number
of separate concentrate sources. Concentrate filter 512 removes any particulate matter from the
concentrate before entering the peritoneal dialysate generation flow path 501. A conductivity
sensor 516 determines the conductivity of the generated peritoneal dialysate after addition of the
concentrates to ensure the peritoneal dialysate has the correct solute concentrations. Flow
sensor 511 determines the flow rate of the fluid after addition of the concentrates. pH sensor
524 determines the pH of the peritoneal dialysate to ensure the peritoneal dialysate has a proper
pH. The peritoneal dialysate can be heated to a desired temperature by heater 525. Temperature
sensor 528 ensures the peritoneal dialysate is heated to an appropriate temperature before
infusion into the patient 538. The heater 525 can be placed at any location in the flow path prior
to delivery to the patient 538. In any embodiment, the heater 525 can be located after the exit of
the sterilization module, particularly if fluid is stored prior to passing through the sterilization
module. The desired temperature of the peritoneal dialysate can be between around 20°C to
around 41°C. As used herein, around 20°C can include between 19.0°C and 21.0°C, and around
41°C can include between 39.0°C and 41.0°C, or similar as understood by those of skill in the
art. In certain embodiments, the desired temperature can be between around 25°C to around
40°C, around 36.5°C to around 37.25°C, around 25°C to around 35°C, or around 30°C to around
40°C. In a preferred embodiment, the desired temperature can be 37 ± 2 °C.
As described, the peritoneal dialysate is sterilized by pumping the peritoneal dialysate
through a sterilization module, which can include first ultrafilter 518, and optionally a second
ultrafilter 520 and/or an optional UV light source (not shown). Pressure sensor 517 measures
the fluid pressure prior to the fluid entering the sterilization module, shown as ultrafilters 518
and 520, and is used in the control circuit to control the pressure. The fluid passes through first
ultrafilter 518, through valve 519, and then through second ultrafilter 520. Connector 523, three
way valve 521, and valve 519 allow backflushing and disinfection of the ultrafilters 518 and
520. The fluid is then pumped into the integrated cycler 539 for use in peritoneal dialysis. As
described, the system can include a dialysate container (not shown) for storage of the generated
peritoneal dialysate until used by the patient 538 at any location, including upstream or
downstream of the sterilization module.
21349709_1:hxa
The integrated cycler 539 includes an infusion line 531 and a drain line 533. Bubble trap
526 traps air bubbles present in the heated dialysate. The air is vented from the system through
bubble trap valve 527. Pressure sensor 529 ensures the pressure of the fluid is within a
predetermined range. The infusion line 531 is connected to a three-way valve 530, which
controls fluid movement between the infusion line 531, the patient 538, and the drain line 533.
The three way valve 530 is connected through connector 532 to a catheter inserted into the
peritoneal cavity of the patient 538. A filter 522 can be included between the three-way valve
530 and the catheter for additional cleaning of the peritoneal dialysate prior to entering a patient
538. In any embodiment, the filter 522 can be a disposable filter. The peritoneal dialysate is
infused into the patient 538 and held for a dwell period. After the dwell period, the fluid is
pumped out of the peritoneal cavity of the patient 538 by drain pump 536. The three-way valve
530 is switched to direct fluid into the drain line 533. Pressure sensor 534 measures the pressure
of fluid in the drain line 531 to ensure proper drainage. Flow meter 535 measures the flow rate
and volume of fluid removed from the patient 538. The drain line 531 is connected to a drain or
waste reservoir 537 through connector 540 for collection and disposal of the used peritoneal
dialysate.
For automated disinfection of the system, connector 540 can be connected to connector
523 to form a flow loop. Disinfectant can be circulated through the flow loop and heated. The
disinfectant can be heated to any temperature capable of disinfecting the system, including
temperatures of at least around equal to 80 °C or greater (≥80) when using citric acid as a
disinfectant. Peracetic acid or bleach can be used to disinfect the system at room temperature.
The disinfectant can be introduced to the flow loop and recirculated at elevated temperatures to
ensure complete disinfection. The disinfectant used can be any suitable disinfectant known in
the art, including peracetic acid, citric acid, or bleach. The connectors and components of the
system can be gamma and autoclave compatible to resist the high temperatures used during
disinfection. The system can be primed by introducing a priming fluid to the peritoneal
dialysate generation flow path 501 and integrated cycler 539.
illustrates an alternative embodiment of the system. Fluid from a water source,
such as water tank 602, can be pumped into the peritoneal dialysate generation flow path 601.
Additionally, or as an alternative to a water tank 602, the system can use a direct connection to a
water source 612. System pump 608 can control the movement of fluid through the peritoneal
dialysate generation flow path 601. If a direct connection to a water source 612 is used, a
21349709_1:hxa
pressure regulator 613 can ensure that an incoming water pressure is within a predetermined
range. The system pumps the fluid from water source 602 or 612 through a water purification
module 603 to remove chemical contaminants in the fluid in preparation for creating dialysate.
After the fluid passes through the water purification module 603, the fluid is pumped to a
concentrate source 604, where necessary components for carrying out peritoneal dialysis can be
added from the concentrate source 604. The concentrates in the concentrate source 604 are
utilized to create a peritoneal dialysis fluid that matches a dialysis prescription. Concentrate
pump 605 and concentrate valve 611 can control the movement of concentrates from the
concentrate source 604 to the peritoneal dialysate generation flow path 601 in a controlled
addition. Alternatively, concentrate valve 611 can be a hose T or backflow restricting hose T.
The concentrates added from the concentrate source 604 to the peritoneal dialysate generation
flow path 601 can include components required for use in peritoneal dialysate. Upon addition of
solutes from the concentrate source 604, the fluid in the peritoneal dialysate generation flow
path 601 can contain all the necessary solutes for peritoneal dialysis. The peritoneal dialysate
should reach a level of sterility for peritoneal dialysis, as described. As shown in the
sterilization module can include one or more of a first ultrafilter 607, a second ultrafilter 609,
and a UV light source 606.
The generated peritoneal dialysate can be pumped directly to an integrated cycler 610 for
immediate infusion into a patient 634. Alternatively, the dialysate can be pumped to an optional
dialysate container 614 as a pre-prepared bolus of solution for storage until ready for use by a
patient 634. Valve 616 can control the movement of fluid to either the dialysate container 614.
Stored dialysate in dialysate container 614 can be pumped as needed to back into the peritoneal
dialysate generation flow path 601 by pump 615 through valve 617. The dialysate container 614
can store enough peritoneal dialysate for a single infusion of peritoneal dialysate into the patient
634, or enough peritoneal dialysate for multiple or continuous infusions into one or multiple
patients.
The generated peritoneal dialysate can be pumped to valve 637. Valve 637 can control
movement of the peritoneal dialysate to any of three options. First, the peritoneal dialysate can
be pumped to integrated cycler 610, second diverted for use with a non-integrated external
cycler 639, or third diverted to a dialysate container 640. All three options can be performed
contemporaneously or selectively. If diverted to the non-integrated external cycler 639, the
21349709_1:hxa
peritoneal dialysate can be pumped via valve 638. Valve 638 can control the movement of the
peritoneal dialysate through either a direct connection to an external cycler 639 or to a dialysate
container 640. Alternative valve and pump configurations for performing the same functions are
contemplated by the present invention. For example, the direct connection to an external cycler
639 can use any type of connector known in the art. The connectors can be single-use or
reusable connectors and should provide for sterile transfer of fluids. The connectors should
preferably be closed connectors, to avoid contact between the fluids and the external
environment. A non-limiting example of a connector that can be used for a direct connection to
an external cycler is the INTACT® connectors provided by Medinstill Development LLC,
Delaware, US. The dialysate container 640 can be heated with an optional heater 641 and then
used in peritoneal dialysis. The connectors to the dialysate container 640 can be any type of
connector known in the art. The connectors can be single use or disposable connectors that
provide transfer of sterile fluids. A non-limiting example of connectors that can be used with
the described system is the Lynx®-Millipore connectors available from Merck KGaA,
Darmstadt, Germany.
The integrated cycler 610 can include a metering pump 619 for metering peritoneal
dialysate into the peritoneal cavity of the patient 634. A heater 618 heats the peritoneal
dialysate to a desired temperature prior to infusion into the patient 634. A pressure regulator
620 ensures the peritoneal dialysate pressure is within a predetermined range safe for infusion
into the patient 634. The metering pump 619 can use any safe pressure for infusing fluid into
the patient 634. Generally, the pump pressures are on average set at ±10.3 kPa or 77.6 mmHg.
If there is no fluid flow, the maximum pressure can increase to ±15.2 kPa or 113.8 mmHg for a
short period, such as less than 10 seconds. The peritoneal dialysate is infused into the peritoneal
cavity of the patient 634 through infusion line 624. After a dwell period, the peritoneal dialysate
is drained from the patient 634 through drain line 623. Pump 622 provides a driving force for
removing the peritoneal dialysate from the patient 634. An optional waste reservoir 621 can be
included to store the used peritoneal dialysate for disposal. Alternatively, the drain line 623 can
be directly connected to a drain for direct disposal. The waste reservoir 621 can be any size,
including between around 12 and around 20 L. For patients requiring a higher drainage, a drain
manifold can be included for connecting multiple waste reservoirs.
Various sensors positioned in the peritoneal dialysate generation and infusion system
ensure that the generated fluid is within predetermined parameters. Flow meter 635 ensures the
21349709_1:hxa
incoming water is at a correct flow rate, while pressure sensor 636 ensures the incoming water is
at an appropriate pressure. Conductivity sensor 625 is used to ensure that the water exiting
water purification module 603 has been purified to a level safe for use in peritoneal dialysis.
Conductivity sensor 626 ensures the conductivity of the dialysate after the addition of
concentrates from concentrate source 604 is within a predetermined range. Refractive index
sensor 627 insures that the concentration of the osmotic agents is within a predetermined range.
pH sensor 628 ensures the pH of the peritoneal dialysate is within a predetermined range. After
passing through the sterilization module including second ultrafilter 609, pH sensor 629 and
conductivity sensor 630 are used to ensure that no changes in the pH or conductivity have
occurred during purification or storage of the dialysate in dialysate container 614. The
integrated cycler 610 has flow meter 631, pressure sensor 632 and temperature sensor 633 to
ensure that the dialysate being infused into the patient 634 is within a proper flow rate, pressure,
and temperature range.
FIG.’s 7A-D illustrate a non-limiting embodiment of the peritoneal dialysate generation
system arranged as a peritoneal dialysate generation cabinet 801. illustrates a
perspective view of the peritoneal dialysate generation cabinet 801, illustrates a front
view of the peritoneal dialysate generation cabinet 801, illustrates a side view of the
peritoneal dialysate generation cabinet 801, and illustrates a back view of the peritoneal
dialysate generation cabinet 801.
A fluid line 805 can connect a water source 804 to the peritoneal dialysate generation
cabinet 801. The fluid line 805 can enter through a connector 828 in a top 806 of the water
source 804. The fluid line 805 connects to the peritoneal dialysate generation flow path as
described with reference to FIG.’s 1 and 5-6 through a back of the peritoneal dialysate
generation cabinet 801 through connector 832 having a fitting 833 for holding the fluid line 805,
as illustrated in . Any of the fluid lines illustrated can be disconnected and removed
from the system for cleaning and replacement. A pump (not shown) can provide a driving force
for the movement of fluid throughout the peritoneal dialysate generation flow path if required.
Water is pumped through the peritoneal dialysate generation cabinet 801 to a water purification
module, shown as sorbent cartridge 812 in FIG.’s 7A-B. The water can enter the sorbent
cartridge 812 through tubing (not shown) connected to the bottom of the sorbent cartridge 812
within the peritoneal dialysate generation cabinet 801. The water exits the sorbent cartridge 812
through connector 813 and tubing 814. An osmotic agent from osmotic agent source 815 and an
21349709_1:hxa
ion concentrate from an ion concentrate source 817 are added to the fluid as described to
generate non-sterilized peritoneal dialysate. The osmotic agent concentrate is added to the fluid
through paddle connector 816. The ion concentrate is added to the fluid through paddle
connector 818. A concentrate pump (not shown) can provide a driving force to move fluid from
the concentrate sources into the peritoneal dialysate generation flow path inside of the peritoneal
dialysate generation cabinet 801. As described, the system can use a single ion concentrate
source in place of the two sources shown in FIG.’s 7A-B, or more than two concentrate sources.
The generated peritoneal dialysate can then be pumped through a sterilization module (not
shown), such as an ultrafilter. A second ultrafilter and/or a UV light source can also be
included. An integrated cycler (not shown in FIG.’s 7A-D) can then pump the dialysate into
infusion line 819 through connector 820 and into the patient. Fitting 825 allows the infusion
line 819 to be removed from the system for cleaning or replacement. Waste fluids can be
pumped out of the system through waste line 807, which connects to the peritoneal dialysate
generation cabinet 801 through connector 830 having fitting 831. A separate waste line for
removing used dialysate from the patient (not shown in FIG.’s 7A-D) can also connect to the
peritoneal dialysate generation cabinet 801 and connect to waste line 807. The waste line 807
enters waste container 808 through a connector 829 in the top 809 of the waste container 808.
Handles 810 and 811 can be included on water source 804 and waste container 808 for easy
movement and storage. Although the peritoneal dialysate generation cabinet 801 is illustrated
on top of table 826 in FIG.’s 8A-D, the peritoneal dialysate generation cabinet 801 can be used
on any stable flat surface.
As described, the peritoneal dialysate generation flow path can include various sensors
for detection of conductivity, pH, refractive index, or other dialysate parameters. The sensors
can be included either inside or outside of the body of the peritoneal dialysate generation cabinet
801. The fluid lines and valves connecting the components of the peritoneal dialysate
generation flow path can likewise be positioned inside of the cabinet body. As described, a top
of the peritoneal dialysate generation cabinet 801 can have a graphical user interface 802
including screen 803. Messages from the control system to the user, or from the user to the
control system, can be generated and read through the graphical user interface 802. The user
can direct the generation of peritoneal dialysate through the graphical user interface 802, and
can receive messages from the system through screen 803. The system can generate alerts to the
user, including any problems detected by any of the sensors, as well as the progress of peritoneal
dialysate generation. A handle 824 can be included for opening the peritoneal dialysate
21349709_1:hxa
generation cabinet 801 to allow access to components on the inside of the cabinet. Handles 821
and 823 can be included to hold the fluid lines and power cord when not in use.
Disinfection connector 822 illustrated in FIG.’s 7A and 7C can be included for
disinfection of the waste line 807. During disinfection, the waste line 807 can be disconnected
from waste container 808 and connected to disinfection connector 822. Disinfectant solution
from a disinfectant source (not shown in FIG.’s 7A-D) can then be circulated through the waste
line 807 to disinfect the waste line 807. Disinfection connector 827 can be included for
disinfection of fluid line 805. Fluid line 805 can be connected to disinfection connector 822 and
disinfection solution can be circulated through the fluid line 805. Drain 834 on water source
804 and drain 835 on waste container 808, allow the water source 804 and waste container 808
to be drained without inverting the containers.
illustrates a peritoneal dialysate generation cabinet 901 using a non-purified water
source, faucet 905 in sink 904. Although illustrated as faucet 905 and sink 904, one of ordinary
skill in the art will understand that any water source can be used. The ability to use municipal or
other non-purified sources of water allow the peritoneal dialysate generation system to work at a
patient’s home without the need to store large amounts of purified water or dialysate. Fitting
906 connects the water line 907 to the faucet 905 or other water source, allowing the water line
907 to be connected or disconnected as necessary. A pump (not shown) can provide a driving
force for the movement of fluid throughout the peritoneal dialysate generation flow path as
described with respect to FIG.’s 1 and 5-6. The water is pumped through the peritoneal
dialysate generation cabinet 901 to a water purification module, shown as sorbent cartridge 911
in The water enters the sorbent cartridge 911 through tubing (not shown) connected to
the bottom of the sorbent cartridge 911 within the peritoneal dialysate generation cabinet 901.
The water exits the sorbent cartridge 911 through connector 926 and tubing 912. An osmotic
agent from osmotic agent source 913 and an ion concentrate from an ion concentrate source 914
are added to the fluid as described to generate non-sterilized peritoneal dialysate. The osmotic
agent concentrate is added to the fluid through paddle connector 916. The ion concentrate is
added to the fluid through paddle connector 915. A concentrate pump (not shown) can provide
a driving force to move fluid from the concentrate sources into the peritoneal dialysate
generation flow path inside of the peritoneal dialysate generation cabinet 901. As described, the
system can use a single ion concentrate source in place of the two sources shown in or
more than two concentrate sources. The generated peritoneal dialysate can then be pumped
21349709_1:hxa
through a sterilization module (not shown), such as an ultrafilter. A second ultrafilter and/or a
UV light source can also be included. An integrated cycler (not shown in can then
pump the dialysate into infusion line 917 through connector 918 and into the patient. Fitting 919
allows the infusion line 917 to be removed from the system for cleaning or replacement. Waste
fluids can be pumped out of the system through waste line 908, which can connect to a drain
909 shown in bathtub 910. A separate drain line (not shown) from the patient can be included to
move used dialysate into the drain 909. Although shown as a bathtub drain 909 in the
waste fluids can be conveyed to any type of drain, or alternatively to a waste container as
illustrated in FIG.’s 7A-D. Although the peritoneal dialysate generation cabinet 901 is
illustrated on top of table 924 in the peritoneal dialysate generation cabinet 901 can be
used on any stable flat surface. In certain embodiments, the peritoneal dialysate generation
cabinet 901 and the patient can be in the same room as the water source and drain 909.
Alternatively, the patient and/or peritoneal dialysate generation cabinet 901 can be in a separate
room, with tubing long enough to reach patient. For longer distances, the tubing should be
strong enough to withstand the pressures necessary in pumping fluid over longer distances.
As described, a top of the peritoneal dialysate generation cabinet 901 can have a
graphical user interface 902 including screen 903. Messages from the control system to the
user, or from the user to the control system, can be generated and read through the graphical
user interface 902. The user can direct the generation of peritoneal dialysate through the
graphical user interface 902, and can receive messages from the system through screen 903.
The system can generate alerts to the user, including any problems detected by any of the
sensors, as well as the progress of peritoneal dialysate generation. A handle 920 can be included
for opening the peritoneal dialysate generation cabinet 901 to allow access to components on the
inside of the cabinet. Handles 921 and 923 can be included to hold the fluid lines and power
cord when not in use.
Disinfection connector 922 can be included for disinfection of the waste line 908.
During disinfection, the waste line 908 can be disconnected from the drain 909 and connected to
disinfection connector 922. Disinfectant solution from a disinfectant source (not shown in can then be circulated through the waste line 908 to disinfect the waste line 908. Disinfection
connector 925 can be included for disinfection of water line 907. The water line 907 can be
disconnected from faucet 905 and connected to disinfection connector 925. Disinfectant
solution can be circulated through the water line 907 for disinfection.
21349709_1:hxa
illustrates an alternative non-limiting embodiment of a peritoneal dialysate
generation flow path 1111. Water from water source 1101 can be pumped into the peritoneal
dialysate generation flow path 1111 by system pump 1103 through connector 1165. Although
shown with screw top 1166 in any method can be used with the water source 1101 to fill
and drain the water source 1101. The water can be pumped through filter 1102 to remove any
particulate matter from the water prior to entering the peritoneal dialysate generation flow path
1111. Alternatively, a dedicated water source, such as a tap or a municipal water source, can be
used in place of water source 1101. Pressure sensor 1104 measures the pressure upstream of
sorbent cartridge 1105. In certain embodiments, an alternative water purification module can be
used in place of sorbent cartridge 1105, including a reverse osmosis module, a nanofilter, a
combination of ion and anion exchange materials, activated carbon, silica, or silica based
columns. The shading in sorbent cartridge 1105 shows varying layers of sorbent material.
However, any order of sorbent material layers can be used, or the sorbent materials can be
intermixed. In the sorbent cartridge 1105 has a fluid inlet 1164 and fluid outlet 1163 in
a base of the sorbent cartridge 1105. In certain embodiments, the fluid inlet 1164 and fluid
outlet 1163 can instead be on opposite sides of the sorbent cartridge 1105. A filter 1106 can
remove particulate matter in the fluid exiting sorbent cartridge 1105.
A first conductivity sensor 1107 can measure the conductivity of the fluid exiting
sorbent cartridge 1105. One or more infusates can be added from ion concentrate source 1109
through connector 1162 to infusate line 1110 by infusate pump 1112 to the peritoneal dialysate
generation flow path 1111 at T-junction 1150. Filter 1151 can remove any particulate matter
from the infusate concentrate prior to reaching the peritoneal dialysate generation flow path
1111. Alternatively, a valve can be used in place of T-junction 1150. A second conductivity
sensor 1108 can measure the conductivity of the fluid after addition of the infusates to ensure
proper concentrations of each infusate. As described, the system can include any number of
infusate sources, each with the same or separate infusate pumps and infusate lines.
An osmotic agent pump 1115 can add an osmotic agent to the peritoneal dialysate
generation flow path 1111 through infusate line 1117 at T-junction 1156. A filter 1152 can
remove any particulate matter from the osmotic agent concentrate. As illustrated in the
system can have multiple osmotic agent sources, including dextrose source 1148 fluidly
connected to osmotic agent line through connector 1154 and icodextrin source 1114 fluidly
connected to osmotic agent line through connector 1160. Filter 1153 can remove particulate
21349709_1:hxa
matter from fluid exiting dextrose source 1148 and filter 1161 can remove particulate matter
form fluid exiting icodextrin source 1114. Alternative osmotic agent sources, including an
amino acid source or a glucose source, can be used in place of, or in addition to, the dextrose
source 1148 and icodextrin source 1114, allowing customization of the osmotic agents used.
Valve 1116 can control the source from which the osmotic agent is obtained. Alternatively,
multiple osmotic agent lines and osmotic agent pumps can be started or stopped to prevent and
direct flow to a desired flow path or component. A flow sensor 1118 measures the flow rate of
fluid through the peritoneal dialysate generation flow path 1111. A composition sensor 1119
can measure the concentrations of the osmotic agents in the fluid, as well as the infusates. The
composition sensor can include a single sensor, or multiple sensors measuring separate fluid
parameters.
Heater 1120 heats the fluid in the peritoneal dialysate generation flow path 1111 to the
patient body temperature. Temperature sensor 1121 measures the temperature of the fluid and
can be used to by a control system to control the heater 1120, heating the fluid to a temperature
of between around 20°C to around 41°C. In a preferred embodiment, the desired temperature
can be 37 ± 2 °C or between 36.5°C to 37.25°C. A control system can monitor the temperature
and shut off flow or generate an alarm if the temperature is outside of the desired range. In
certain embodiments, the control system can shut off flow if the temperature is equal to greater
than around 41 °C. Pressure sensor 1122 measures the pressure of the fluid prior to entering a
dialysate sterilization module.
The dialysate sterilization module can include a first ultrafilter 1123 and a second
ultrafilter 1124 fluidly connected by fluid line 1159. The fluid flows through both ultrafilters to
remove any chemical or biological contaminants. Waste fluid can exit the first ultrafilter 1123
through fluid line 1130 and exit the second ultrafilter 1124 through fluid line 1129. Valves
1149 and 1128 control the movement of fluid between the first ultrafilter 1123 and second
ultrafilter 1124 into waste line 1131, which is fluidly connected to fluid line 1130 at T-junction
1167. Valves 1149 and 1128 can be used to modulate the fluid movement out of ultrafilters
1123 and 1124 to ensure sufficient pressure for ultrafiltration. If the pressure in ultrafilter 1124
decreases below a necessary value, valve 1128 can be closed, preventing fluid movement from
ultrafilter 1123 into fluid line 1130 and increasing the pressure in ultrafilter 1124. The waste
line 1131 is fluidly connected to a waste line 1134 at T-junction 1168 and to waste reservoir
1133 through connector 1169, or alternatively, to a drain. Although shown with a screw top
21349709_1:hxa
1170 and tap 1171, one of skill in the art will understand that alternative methods for filling and
draining waste reservoir 1133 can be used.
Fluid exiting the second ultrafilter 1124 passes through optional control valve 1125.
Control valve 1125 can selectively direct fluid into either fluid line 1113 and an integrated
cycler or into fluid line 1126 for addition to the dextrose source 1148 and icodextrin source
1114 via T-junction 1155. The fluid can be added to dextrose source 1148 and icodextrin source
1114 to dissolve solid icodextrin and solid dextrose prior to generating the peritoneal dialysate.
Fluid line 1113 can include a pressure sensor 1127 to ensure that the fluid pressure is
within predetermined limits prior to entering the integrated cycler. Valve 1135 controls the
movement of fluid from the sterilization module. Valve 1136 controls the movement of fluid
into and out of the integrated cycler through cycler line 1138.
The cycler line 1138 can include a second temperature sensor 1139 to ensure the proper
temperature of the peritoneal dialysate prior to infusion into the patient 1147. An air detector
1141 is included to detect any air that would otherwise be introduced into the patient 1147. A
bubble trap (not shown) can be included to remove any detected air. A flow sensor 1143
measures the flow rate of fluid in the cycler line 1138 and can be used to control the amount of
peritoneal dialysate infused into the patient 1147. A pressure sensor 1142 can be included to
ensure the fluid pressure in cycler line 1138 is within predetermined limits for infusion into the
patient 1147. A catheter 1140 can connect to the cycler line 1138 at connection 1144. In certain
embodiments, a heparin syringe 1146 can be included to add heparin or other medication to the
peritoneal dialysate. Filter 1145 removes any particulate matter prior to infusion into the patient
1147.
After a dwell period, the spent peritoneal dialysate can be drained from the patient 1147
through the cycler line 1138. Drain pump 1132 can provide the driving force for draining the
spent peritoneal dialysate. The spent peritoneal dialysate passes through valves 1136 and 1137
and into drain line 1134, which can fluidly connect to waste reservoir 1133 or to a drain.
As illustrated in the peritoneal dialysate generation system can include a purity
control system having a first ultrafilter 1123 and second ultrafilter 1124 for sterilization of the
peritoneal dialysate, as well as control valve 1125, valves 1128, 1135, and 1149, pressure
sensors 1122 and 1127, and fluid lines 1113, 1126, 1129, 1130, 1131, and 1159, as indicated by
21349709_1:hxa
dashed box 1173. The peritoneal dialysate generation system can include the water source
1102, sorbent cartridge 1105, peritoneal dialysate generation flow path 1111, heater 1120 and
temperature sensor 1121 as indicated in dashed box 1172. The second ultrafilter 1124 can be
fluidly connected to control valve 1125, which is fluidly connected to fluid lines 1113 and 1126.
The generated peritoneal dialysate is selectively directed by control valve 1125 to valve 1135
and the integrated cycler for infusion into the patient 1147. Prior to generation of the peritoneal
dialysate, icodextrin source 1114 and dextrose source 1148 can contain solids. Water from
water source 1101 can be added to icodextrin source 1114 and dextrose source 1148 to generate
dextrose or icodextrin concentrates having a known concentration. To ensure that the icodextrin
source 1114 and dextrose source 1148 remain free from chemical or biological contamination,
the water can first be passed through the purity control system, including first ultrafilter 1123
and second ultrafilter 1124 prior to addition to the osmotic agent sources. Control valve 1125
can selectively direct the water from the second ultrafilter 1124 through fluid line 1126 and into
each of icodextrin source 1114 and dextrose source 1148 via infusate line 1117 to generate
osmotic agent concentrates free from contamination. As described, the peritoneal dialysate
generation system can include any number of osmotic agent sources, wherein the second
ultrafilter 1124 can be fluidly connected to each osmotic agent source. Although not illustrated
in the second ultrafilter 1124 can also be fluidly connected to the ion concentrate source
1109 to generate an infusate concentrate free from chemical or biological contamination.
Pumping water from the second ultrafilter 1124 to the icodextrin source 1114 and dextrose
source 1148 also allows the use of heated water in generating the osmotic agent concentrates.
The water can be heated by heater 1120 prior to pumping the water through the purity control
system. Using heated water can speed up the dissolution of the osmotic agents to generate
osmotic agent concentrates more quickly. By using solid dry powders as the osmotic agent
sources, which are then dissolved with sterilized water, the formation of glucose degradation
products is reduced, which can preserve peritoneal membrane function and allow patients to
remain on peritoneal dialysis for a longer period of time and with higher quality of life, due to
fewer complications related to chronic inflammation of the peritoneum. Optional Vibration
plate 1157 can agitate the solution in icodextrin source 1114, and optional vibration plate 1158
can agitate the solution in dextrose source 1148 to further speed dissolution of the osmotic
agents. One of skill in the art will understand that alternative means of agitation can be used,
including stirrers or other mixers.
21349709_1:hxa
The purity control system can also include a pressure sensor 1122 in the fluid line fluidly
connecting the first ultrafilter 1123 to the peritoneal dialysate generation flow path 1111. Proper
use of the ultrafilters can require a specific pressure range for the fluid flowing through the
purity control system. Pressure sensor 1122 can be in communication with a control system that
can stop or change the rate of the system pump 1103 to adjust a peritoneal dialysate flow rate if
the pressure is outside of the predetermined range. In certain embodiments, the control system
can adjust the peritoneal dialysate flow rate to maintain a pressure of between…
Pressure sensor 1127 measures the pressure of the fluid exiting second ultrafilter 1124.
The pressure of fluid exiting second ultrafilter 1124 must be within a safe range for infusion into
the patient 1147. A control system can control the system pump 1103 to adjust the peritoneal
dialysate flow rate and maintain the pressure within a predetermined range exiting the second
ultrafilter 1124. In certain embodiments, the system can automatically generate an alert if the
pressure at either or both of pressure sensor 1127 or 1122 is outside of a predetermined range.
In certain embodiments, the control system can adjust the peritoneal dialysate flow rate to
maintain a pressure of between -200 mmHg to 500 mmHg, from -50 mmHg to 100 mmHg, from
0 mmHg to 100 mmHg, from -50 mmHg to 200 mm Hg, from 200 mmHg to 500 mmHg, or
from 100 mmHg to 400 mmHg.
One skilled in the art will understand that various combinations and/or modifications and
variations can be made in the described systems and methods depending upon the specific needs
for operation. Moreover, features illustrated or described as being part of an aspect of the
invention may be used in the aspect of the invention, either alone or in combination, or follow a
preferred arrangement of one or more of the described elements.
21349709_1:hxa
Claims (16)
1. A purity control system for use in peritoneal dialysis, the purity and control system comprising: a first fluid line fluidly connected to a peritoneal dialysate generation system and a first ultrafilter; a second fluid line fluidly connecting the first ultrafilter to a second ultrafilter; the peritoneal dialysate generation system comprising at least a water source, an osmotic agent source, an ion concentrate source, and a water purification module fluidly connected to a peritoneal dialysate generation flow path.
2. The purity and control system of claim 1, wherein the second ultrafilter is fluidly connected to a control valve; the control valve selectively directing fluid to either the peritoneal dialysate generation system or an integrated cycler.
3. The purity control system of claim 2, the control valve fluidly connected to the peritoneal dialysate generation system at an infusate line.
4. The purity control system of claim 1, further comprising a pressure sensor in the first fluid line.
5. The purity control system of claim 2, further comprising a pressure sensor in a third fluid line fluidly connecting the control valve and the integrated cycler.
6. The purity control system of claim 1, the first ultrafilter fluidly connected to a fourth fluid line; the fourth fluid line fluidly connected to a waste line.
7. The purity control system of claim 6, the waste line fluidly connectable to a waste reservoir.
8. The purity control system of claim 6, the waste line fluidly connectable to a drain.
9. The purity control system of claim 6, the second ultrafilter fluidly connected to a fifth fluid line; the fifth fluid line fluidly connected to the waste line. 21349709_1:hxa
10. The purity control system of claim 9, the fourth fluid line having a valve positioned between the first ultrafilter and the waste line; and the fifth fluid line having a valve positioned between the second ultrafilter and the waste line.
11. The purity control system of claim 1, further comprising a second valve positioned on a third fluid line fluidly connecting the second ultrafilter to the integrated cycler.
12. The purity control system of claim 4, further comprising a control system, the control system controlling a peritoneal dialysate flow rate based on data from the pressure sensor.
13. The purity control system of claim 12, the controller controlling the peritoneal dialysate flow rate to maintain a pressure of the peritoneal dialysate between -200 mmHg to 500 mmHg, from -50 mmHg to 100 mmHg, from 0 mmHg to 100 mmHg, from -50 mmHg to 200 mm Hg, from 200 mmHg to 500 mmHg, or from 100 mmHg to 400 mmHg
14. The purity control system of claim 5, further comprising a control system, the control system controlling a peritoneal dialysate flow rate based on data from the pressure sensor.
15. The purity control system of claim 14, the control system controlling the peritoneal dialysate flow rate to maintain a pressure of the peritoneal dialysate between -200 mmHg to 500 mmHg, from -50 mmHg to 100 mmHg, from 0 mmHg to 100 mmHg, from -50 mmHg to 200 mm Hg, from 200 mmHg to 500 mmHg, or from 100 mmHg to 400 mmHg
16. The purity control system of claim 1, the water purification module comprising a sorbent cartridge. Medtronic, Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON & FERGUSON 21349709_1:hxa
Publications (1)
Publication Number | Publication Date |
---|---|
NZ746796A true NZ746796A (en) |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170281846A1 (en) | Peritoneal dialysate fluid generation system with integrated cycler | |
US20170281847A1 (en) | Regenerative peritoneal dialysis system | |
US20180021501A1 (en) | Peritoneal dialysate preparation and sensor system | |
AU2018201715B2 (en) | System and method for performing alternative and sequential blood and peritoneal dialysis modalities | |
ES2949142T3 (en) | Peritoneal dialysis system with preparation of dialysis fluid at the point of use thus including mixing and heating | |
US20180043081A1 (en) | Peritoneal dialysate purity control system | |
CN108778363B (en) | Peritoneal dialysis solution fluid generation system | |
US20180021500A1 (en) | Peritoneal dialysate temperature regulation system | |
EP3466460A1 (en) | Peritoneal dialysate temperature regulation system | |
AU4160500A (en) | Method, apparatus and components of dialysis system | |
EP3466461A1 (en) | Peritoneal dialysate purity control system | |
EP3466459A1 (en) | Peritoneal dialysate preparation and sensor system | |
NZ746796A (en) | Peritoneal dialysate purity control system | |
NZ746233A (en) | Peritoneal dialysate preparation and sensor system | |
US20230390473A1 (en) | Medical fluid generation system | |
US20230128863A1 (en) | Inline heater for a peritoneal dialysis system | |
US20230405196A1 (en) | Medical fluid generation system | |
EP3903851A1 (en) | Peritoneal dialysis fluid from concentrate containers |